The Influence of PTAB Proceedings on Bio/Pharma Patents

McDonnell Boehnen Hulbert & Berghoff LLP partners Dr. Paula Fritsch and Alison Baldwin are featured presenters for an iBIO hosted event set for 8:30-10:00 a.m. on June 19 at Horizon Pharma in Lake Forest, IL. MBHB is a proud sponsor of the presentation.

About the Presentation 

Inter partes review (IPR) and Post-Grant Review (PGR) proceedings before the Patent Trial and Appeal Board (PTAB) have become increasingly popular mechanisms to challenge bio/pharma patents. While the full impact of the Supreme Court’s recent Oil States and SAS decisions has yet to play out, both petitioners and patent owners can learn lessons from the hundreds of IPR petitions that have been filed challenging bio/pharma patents. Join us as we discuss the following topics:

  • A review of how bio/pharma patents have fared before the PTAB;
  • An analysis of how PTAB proceedings are impacting ANDA and biosimilar litigations;
  • A discussion of strategies for petitioners and patent owners in IPRs and PGRs challenging bio/pharma patents; and
  • A discussion of how the Supreme Court’s recent to grant cert in Oil States and SAS decisions could impact PTAB invalidity proceedings in the bio/pharma space.


View details here